StockNews.AI
TMDX
StockNews.AI
117 days

TransMedics to Report First Quarter 2025 Financial Results on May 8, 2025

1. TransMedics will announce Q1 2025 financial results on May 8, 2025. 2. The management, led by TransMedics team, will hold a conference call. 3. TransMedics leads in organ transplant technology for heart, lung, and liver failure. 4. They aim to improve organ quality and increase donor organ utilization.

4m saved
Insight
Article

FAQ

Why Bullish?

The upcoming financial results and focus on innovative organ transplant technologies can positively influence TMDX's stock performance, similar to prior earnings releases that resulted in stock rallies.

How important is it?

The announcement of financial results is critical for investor sentiment and potential stock price movements.

Why Short Term?

The earnings call could lead to immediate reactions in the stock price, especially if results meet or exceed market expectations.

Related Companies

NVTAISRGBAX
, /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the first quarter 2025 after market close on Thursday, May 8, 2025. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT. Investors interested in listening to the conference call may do so by dialing (844) 676-6010 for domestic callers or (412) 634-6944 for international callers and ask to be joined into the TransMedics call. A live and archived webcast of the event will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com/. About TransMedics Group, Inc.TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure. Investor Contact:Brian JohnstonLaine Morgan332-895-3222[email protected] SOURCE TransMedics Group, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News